Nuala Moran

Researchers at top US universities have gone on the offensive against NIH cuts, saying they will wipe out a generation of junior scientists.

A new government policy paper puts the emphasis on public procurement, lead markets and a more international approach.

The UK biotech sector has fallen victim to the mayhem in the capital markets. After a year of falling share prices, five quoted companies have put up “for sale” signs.

The UK government’s minor concession on an 80 per cent increase in capital gains tax on selling start-ups won’t win back entrepreneurs

Since 1996 Index Ventures has invested in seed and early stage start-ups. Now it says Europe’s start-ups are more mature and need care and capital to stay in control.

Anti-trust legislation, particularly involving raids at dawn, is no way to improve productivity in the pharmaceutical industry, says Nuala Moran.

As Framework Programme 7 fires up, Europe’s auditors throw on some cold water. Nuala Moran wonders how we will assess whether it has all been worthwhile.

Three days before Brussels unveiled its Strategic Energy Technology Policy, the UK Prime Minister set out his vision for applying technology to create a low carbon economy.

Today, the European Union sets out its research strategy for energy – looking to find the low-carbon technology fix for climate change.

The WHO is looking to patent pools to prevent blocking IP and give earlier access to generics manufacturers as part of a plan to improve healthcare in developing countries.